Itoco (Dorzolamide)

Dorzolamide blocks carbonic anhydrase enzymes in the ciliary body of the eye. This inhibition reduces the production of aqueous humor, the fluid that maintains eye pressure, thereby lowering intra‑ocular pressure and helping to control glaucoma.

The dosing regimen for Itoco is determined by the prescribing eye specialist. Typically, one drop is instilled in the affected eye(s) one to two times daily, but the exact schedule should follow the clinician’s instructions.

Safety data for dorzolamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Itoco, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itoco (dorzolamide) belongs to the carbonic anhydrase inhibitor class, which reduces aqueous humor production. Compared with beta‑blocker eye drops, it works via a different mechanism and may be combined for additive effect. Unlike prostaglandin analogues that increase outflow, dorzolamide focuses on decreasing fluid formation.

Itoco should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from direct sunlight and moisture to maintain stability and potency.

Itoco is applied as an ophthalmic solution. The patient places the prescribed number of drops into the affected eye(s) as directed by the eye care professional, typically avoiding contact with the eyelid or eyelashes and washing hands before and after use.

Serious risks include severe allergic reactions such as angio‑edema or anaphylaxis, and rare dermatologic conditions like Stevens‑Johnson syndrome. Any signs of swelling, rash, or sudden vision changes should prompt immediate medical attention.

Patients with a known hypersensitivity to dorzolamide, sulfonamides, or any component of the formulation should avoid Itoco. Additionally, individuals with severe renal impairment or those who cannot safely administer eye drops should discuss alternatives with their clinician.